• Oral Administration:
  
  
  • Trikafta comes in the form of a fixed-dose combination tablet.
    
    
  • Take one tablet once daily with fatty food (e.g., peanut butter, eggs, or cheese), which helps enhance absorption.
    
    
  • Do not crush or chew the tablet; swallow it whole with a glass of water.
    
    
• Missed Dose:
  
  
  • If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In that case, skip the missed dose and take your next dose at the usual time. Do not take two doses at once to make up for a missed dose.
    
    
• Storage:
  
  
  • Store the medication in a cool, dry place, away from moisture and heat.
    
    
  • Keep the medication in its original container and ensure it is out of reach of children.
    
    

The CFTR protein plays a critical role in regulating the transport of chloride ions across cell membranes. In cystic fibrosis, mutations in the CFTR gene cause the protein to malfunction, which leads to thick and sticky mucus buildup in the lungs, digestive system, and other organs. This causes the characteristic symptoms of cystic fibrosis, such as respiratory infections, lung damage, and difficulty digesting food.

Elexacaftor, Ivacaftor, and Tezacaftor work together in the following ways:

• Elexacaftor: Helps the defective CFTR protein to fold properly and reach the surface of the cell, where it can function more effectively. This improves the overall activity of the CFTR protein at the cell surface.
  
  
• Tezacaftor: Works in a similar manner to Elexacaftor by helping the CFTR protein fold correctly and move to the cell surface, where it can carry out its functions.
  
  
• Ivacaftor: Once the CFTR protein reaches the cell surface, Ivacaftor helps the protein open the CFTR channels properly and keep them open, allowing chloride ions to flow freely across the cell membrane, which restores proper fluid balance in cells and tissues.
  
  

Together, this combination significantly improves the function of the CFTR protein, leading to better lung function, fewer lung infections, and improved overall health for individuals with cystic fibrosis.

While Elexacaftor, Ivacaftor, and Tezacaftor are generally well-tolerated, some side effects can occur. Common side effects include:

• Headache: One of the most commonly reported side effects.
  
  
• Diarrhea: Some patients may experience loose stools or diarrhea when starting the treatment.
  
  
• Nausea: Feelings of nausea or mild stomach upset are possible.
  
  
• Upper Respiratory Tract Infections: Some individuals may experience symptoms like a runny nose or sinus congestion.
  
  
• Liver Issues: Trikafta can sometimes cause an increase in liver enzymes, indicating potential liver problems. Monitoring liver function is crucial.
  
  
• Rash: Skin reactions like rashes or itching may occur in some individuals.
  
  
• Fatigue: Some patients have reported feeling tired or fatigued after starting treatment.
  
  
• Increased Blood Pressure: Some people may experience a slight increase in blood pressure.
  
  

If any side effects become severe or persist, it’s important to consult with a healthcare provider for further advice and possible adjustments to the treatment.

• Liver Health: Trikafta may affect liver function, so it is crucial to monitor liver enzymes during treatment. People with existing liver disease should use this medication with caution.
  
  
• Pregnancy and Breastfeeding: It is not yet known if Trikafta is safe for use during pregnancy or breastfeeding. Pregnant or breastfeeding women should consult with a healthcare provider before starting this medication.
  
  
• Drug Interactions: Always inform your doctor about other medications you are taking to avoid potentially dangerous interactions, especially with CYP3A4 inhibitors or inducers.
  
  

Age Considerations: Trikafta is approved for use in children aged 12 years and older. The safety and efficacy in children under 12 years have not been fully established.

• CYP3A4 Inhibitors: Since Ivacaftor is metabolized by the enzyme CYP3A4, medications that inhibit this enzyme (e.g., ketoconazole, ritonavir, or clarithromycin) can increase the levels of Ivacaftor in the blood, potentially increasing the risk of side effects. In such cases, dose adjustments may be necessary.
  
  
• CYP3A4 Inducers: Conversely, CYP3A4 inducers (such as rifampin, phenytoin, or carbamazepine) can lower the levels of Ivacaftor in the blood, which could reduce its effectiveness. Dose adjustments may also be necessary.
  
  
• Liver Disease: People with liver problems should be carefully monitored, as impaired liver function may affect the metabolism of these medications. Dosage adjustments may be required for patients with liver impairment.
  
  

Other Medications: It is important to consult with your healthcare provider if you are taking other medications, as they may interact with Trikafta or affect its efficacy.

• Initial Dose: The standard dose is one tablet daily containing Elexacaftor 100 mg, Tezacaftor 50 mg, and Ivacaftor 75 mg.
  
  

Dosage Adjustments: In patients with liver disease, a lower dose may be recommended. Always follow your healthcare provider’s instructions regarding dosage adjustments.

Elexacaftor, Ivacaftor, and Tezacaftor are prescription medications. A doctor will determine if this treatment is appropriate based on the patient’s genetic profile (specifically for the F508del mutation), medical history, and other treatments they may be taking. Regular monitoring for liver function and potential side effects is recommended during the course of treatment.

• What is Elexacaftor, Ivacaftor, and Tezacaftor used for?
  It is prescribed to treat cystic fibrosis (CF) in patients with certain gene mutations.

• How do these medications work together?
  They target defective CFTR proteins, improving chloride transport and lung function.

• At what age can patients start using this combination?
  It is FDA-approved for patients 2 years and older with eligible CF mutations.

• How is this medication taken?
  It is usually taken orally as tablets with fatty food to improve absorption.

• What are the common side effects?
  Headache, diarrhea, abdominal pain, increased liver enzymes, and rash.

• Can it cause serious side effects?
  Yes—serious liver problems and cataracts in children have been reported.

• Do patients need genetic testing before using it?
  Yes, genetic testing confirms eligibility based on CFTR mutations.

• How effective is this treatment?
  It has shown significant improvement in lung function, quality of life, and reduced hospitalizations.

• Can this medication be used with other CF treatments?
  Yes, but always under medical supervision to avoid interactions.

• Are there any drug interactions to be aware of?
  Yes—strong CYP3A inducers or inhibitors can alter drug levels.

• Is this a cure for cystic fibrosis?
  No, but it is a highly effective treatment that manages symptoms and slows disease progression.

• Can children and adolescents take this therapy?
  Yes, it is approved for pediatric use from 2 years of age.

• How long do patients need to take it?
  It is a long-term treatment, usually continued for life unless advised otherwise.

• Do patients need liver monitoring while on this therapy?
  Yes, regular liver function tests are required due to potential liver toxicity.

• Can pregnant or breastfeeding women take this medication?
  Use should be carefully considered; consult with a healthcare provider.

• Does this medication improve life expectancy?
  Yes, by reducing lung infections and preserving lung function, it contributes to longer survival.

• How soon do patients see improvements?
  Many notice improvements in breathing and energy within weeks of starting therapy.

• Is there a risk of resistance developing?
  No, since it targets protein function rather than bacteria or viruses.

• Why is this medication considered a breakthrough in CF care?
  It treats the underlying cause of CF rather than just symptoms.

• What should patients do if they miss a dose?
  Take it as soon as remembered unless it’s close to the next dose—never double up.